(RTTNews) - Viking Therapeutics, Inc. (VKTX), Wednesday announced positive data from Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal ...
Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...
SAN DIEGO, July 19, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results